Towards a personalized treatment approach for SCD

Raffaella Colombatti, MD, PhD, University of Padova, Padova, Italy, discusses personalized treatment in sickle cell disease (SCD), highlighting the importance of better understanding the biology of SCD and of finding novel biomarkers to eventually allow patients to achieve a quality of life (QoL) comparable to that of healthy individuals. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.